Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unknown × catumaxomab × Clear all
NCT04819399 2022-04-05

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Lindis Biotech GmbH

Phase 1 Unknown
30 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡